221 related articles for article (PubMed ID: 31645659)
1. WZ66, a novel acetyl-CoA carboxylase inhibitor, alleviates nonalcoholic steatohepatitis (NASH) in mice.
Gao YS; Qian MY; Wei QQ; Duan XB; Wang SL; Hu HY; Liu J; Pan CY; Zhang SQ; Qi LW; Zhou JP; Zhang HB; Wang LR
Acta Pharmacol Sin; 2020 Mar; 41(3):336-347. PubMed ID: 31645659
[TBL] [Abstract][Full Text] [Related]
2. Selective Acetyl-CoA Carboxylase 1 Inhibitor Improves Hepatic Steatosis and Hepatic Fibrosis in a Preclinical Nonalcoholic Steatohepatitis Model.
Tamura YO; Sugama J; Iwasaki S; Sasaki M; Yasuno H; Aoyama K; Watanabe M; Erion DM; Yashiro H
J Pharmacol Exp Ther; 2021 Nov; 379(3):280-289. PubMed ID: 34535562
[TBL] [Abstract][Full Text] [Related]
3. Acetyl-CoA Carboxylase Inhibition Improves Multiple Dimensions of NASH Pathogenesis in Model Systems.
Ross TT; Crowley C; Kelly KL; Rinaldi A; Beebe DA; Lech MP; Martinez RV; Carvajal-Gonzalez S; Boucher M; Hirenallur-Shanthappa D; Morin J; Opsahl AC; Vargas SR; Bence KK; Pfefferkorn JA; Esler WP
Cell Mol Gastroenterol Hepatol; 2020; 10(4):829-851. PubMed ID: 32526482
[TBL] [Abstract][Full Text] [Related]
4. Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation.
Bates J; Vijayakumar A; Ghoshal S; Marchand B; Yi S; Kornyeyev D; Zagorska A; Hollenback D; Walker K; Liu K; Pendem S; Newstrom D; Brockett R; Mikaelian I; Kusam S; Ramirez R; Lopez D; Li L; Fuchs BC; Breckenridge DG
J Hepatol; 2020 Oct; 73(4):896-905. PubMed ID: 32376414
[TBL] [Abstract][Full Text] [Related]
5. Acetyl-CoA carboxylase 1 and 2 inhibition ameliorates steatosis and hepatic fibrosis in a MC4R knockout murine model of nonalcoholic steatohepatitis.
Matsumoto M; Yashiro H; Ogino H; Aoyama K; Nambu T; Nakamura S; Nishida M; Wang X; Erion DM; Kaneko M
PLoS One; 2020; 15(1):e0228212. PubMed ID: 31990961
[TBL] [Abstract][Full Text] [Related]
6. Coordinated changes of gut microbiome and lipidome differentiates nonalcoholic steatohepatitis (NASH) from isolated steatosis.
Qian M; Hu H; Yao Y; Zhao D; Wang S; Pan C; Duan X; Gao Y; Liu J; Zhang Y; Yang S; Qi LW; Wang L
Liver Int; 2020 Mar; 40(3):622-637. PubMed ID: 31782595
[TBL] [Abstract][Full Text] [Related]
7. GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH).
Alkhouri N; Lawitz E; Noureddin M; DeFronzo R; Shulman GI
Expert Opin Investig Drugs; 2020 Feb; 29(2):135-141. PubMed ID: 31519114
[No Abstract] [Full Text] [Related]
8. Targeting ACC for NASH resolution.
Zhang XJ; Cai J; Li H
Trends Mol Med; 2022 Jan; 28(1):5-7. PubMed ID: 34844875
[TBL] [Abstract][Full Text] [Related]
9. A small molecule targeting ALOX12-ACC1 ameliorates nonalcoholic steatohepatitis in mice and macaques.
Zhang XJ; Ji YX; Cheng X; Cheng Y; Yang H; Wang J; Zhao LP; Huang YP; Sun D; Xiang H; Shen LJ; Li PL; Ma JP; Tian RF; Yang J; Yao X; Xu H; Liao R; Xiao L; Zhang P; Zhang X; Zhao GN; Wang X; Hu ML; Tian S; Wan J; Cai J; Ma X; Xu Q; Wang Y; Touyz RM; Liu PP; Loomba R; She ZG; Li H
Sci Transl Med; 2021 Dec; 13(624):eabg8116. PubMed ID: 34910548
[TBL] [Abstract][Full Text] [Related]
10. Acetyl-CoA Carboxylase Inhibitor GS-0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients With Nonalcoholic Steatohepatitis.
Lawitz EJ; Coste A; Poordad F; Alkhouri N; Loo N; McColgan BJ; Tarrant JM; Nguyen T; Han L; Chung C; Ray AS; McHutchison JG; Subramanian GM; Myers RP; Middleton MS; Sirlin C; Loomba R; Nyangau E; Fitch M; Li K; Hellerstein M
Clin Gastroenterol Hepatol; 2018 Dec; 16(12):1983-1991.e3. PubMed ID: 29705265
[TBL] [Abstract][Full Text] [Related]
11. Optimizing the Benefit/Risk of Acetyl-CoA Carboxylase Inhibitors through Liver Targeting.
Huard K; Smith AC; Cappon G; Dow RL; Edmonds DJ; El-Kattan A; Esler WP; Fernando DP; Griffith DA; Kalgutkar AS; Ross TT; Bagley SW; Beebe D; Bi YA; Cabral S; Crowley C; Doran SD; Dowling MS; Liras S; Mascitti V; Niosi M; Pfefferkorn JA; Polivkova J; Préville C; Price DA; Shavnya A; Shirai N; Smith AH; Southers JR; Tess DA; Thuma BA; Varma MV; Yang X
J Med Chem; 2020 Oct; 63(19):10879-10896. PubMed ID: 32809824
[TBL] [Abstract][Full Text] [Related]
12. Acetyl-CoA carboxylase inhibitor increases LDL-apoB production rate in NASH with cirrhosis: prevention by fenofibrate.
Dandan M; Han J; Mann S; Kim R; Li K; Mohammed H; Chuang JC; Zhu K; Billin AN; Huss RS; Chung C; Myers RP; Hellerstein M
J Lipid Res; 2023 Mar; 64(3):100339. PubMed ID: 36737040
[TBL] [Abstract][Full Text] [Related]
13. Discovery of a novel olefin derivative as a highly potent and selective acetyl-CoA carboxylase 2 inhibitor with in vivo efficacy.
Nishiura Y; Matsumura A; Kobayashi N; Shimazaki A; Sakamoto S; Kitade N; Tonomura Y; Ino A; Okuno T
Bioorg Med Chem Lett; 2018 Aug; 28(14):2498-2503. PubMed ID: 29903660
[TBL] [Abstract][Full Text] [Related]
14. Liraglutide improves hepatic steatosis and metabolic dysfunctions in a 3-week dietary mouse model of nonalcoholic steatohepatitis.
Duparc T; Briand F; Trenteseaux C; Merian J; Combes G; Najib S; Sulpice T; Martinez LO
Am J Physiol Gastrointest Liver Physiol; 2019 Oct; 317(4):G508-G517. PubMed ID: 31460789
[TBL] [Abstract][Full Text] [Related]
15. Targeted Delivery of Stk25 Antisense Oligonucleotides to Hepatocytes Protects Mice Against Nonalcoholic Fatty Liver Disease.
Cansby E; Nuñez-Durán E; Magnusson E; Amrutkar M; Booten SL; Kulkarni NM; Svensson LT; Borén J; Marschall HU; Aghajan M; Mahlapuu M
Cell Mol Gastroenterol Hepatol; 2019; 7(3):597-618. PubMed ID: 30576769
[TBL] [Abstract][Full Text] [Related]
16. Acetyl CoA Carboxylase Inhibition Reduces Hepatic Steatosis but Elevates Plasma Triglycerides in Mice and Humans: A Bedside to Bench Investigation.
Kim CW; Addy C; Kusunoki J; Anderson NN; Deja S; Fu X; Burgess SC; Li C; Ruddy M; Chakravarthy M; Previs S; Milstein S; Fitzgerald K; Kelley DE; Horton JD
Cell Metab; 2017 Aug; 26(2):394-406.e6. PubMed ID: 28768177
[TBL] [Abstract][Full Text] [Related]
17. Combinations of an acetyl CoA carboxylase inhibitor with hepatic lipid modulating agents do not augment antifibrotic efficacy in preclinical models of NASH and fibrosis.
Vijayakumar A; Okesli-Armlovich A; Wang T; Olson I; Seung M; Kusam S; Hollenback D; Mahadevan S; Marchand B; Toteva M; Breckenridge DG; Trevaskis JL; Bates J
Hepatol Commun; 2022 Sep; 6(9):2298-2309. PubMed ID: 35735253
[TBL] [Abstract][Full Text] [Related]
18. Wheat-bran autolytic peptides containing a branched-chain amino acid attenuate non-alcoholic steatohepatitis via the suppression of oxidative stress and the upregulation of AMPK/ACC in high-fat diet-fed mice.
Kawaguchi T; Ueno T; Nogata Y; Hayakawa M; Koga H; Torimura T
Int J Mol Med; 2017 Feb; 39(2):407-414. PubMed ID: 28000843
[TBL] [Abstract][Full Text] [Related]
19. A bacteria-derived tetramerized protein ameliorates nonalcoholic steatohepatitis in mice via binding and relocating acetyl-coA carboxylase.
Lin Y; Yang M; Huang L; Yang F; Fan J; Qiang Y; Chang Y; Zhou W; Yan L; Xiong J; Ping J; Chen S; Men D; Li F
Cell Rep; 2023 Nov; 42(11):113453. PubMed ID: 37976162
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and biological evaluation of novel spiro-pentacylamides as acetyl-CoA carboxylase inhibitors.
Wei Q; Mei L; Yang Y; Ma H; Chen H; Zhang H; Zhou J
Bioorg Med Chem; 2018 Aug; 26(14):3866-3874. PubMed ID: 30049586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
